Efficacy of tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma: the Korean Society of Pediatric Hematology-Oncology experience over 6 years (2000-2005).
The efficacy of tandem high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) was investigated in patients with high-risk neuroblastoma. Patients over 1 yr of age who were newly diagnosed with stage 4 neuroblastoma from January 2000 to December 2005 were enrolled in The Korean Society of Pediatric Hematology-Oncology registry. All patients who were assigned to receive HDCT/ASCR at diagnosis were retrospectively analyzed to investigate the efficacy of single or tandem HDCT/ASCR. Seventy and 71 patients were assigned to receive single or tandem HDCT/ASCR at diagnosis. Fifty-seven and 59 patients in the single or tandem HDCT group underwent single or tandem HDCT/ASCR as scheduled. Twenty-four and 38 patients in the single or tandem HDCT group remained event free with a median follow-up of 56 (24-88) months. When the survival rate was analyzed according to intent-to-treat at diagnosis, the probability of the 5-yr event-free survival+/-95% confidence intervals was higher in the tandem HDCT group than in the single HDCT group (51.2+/-12.4% vs. 31.3+/-11.5%, P=0.030). The results of the present study demonstrate that the tandem HDCT/ASCR strategy is significantly better than the single HDCT/ASCR strategy for improved survival in the treatment of high-risk neuroblastoma patients.
Sung
Ki Woong
KW
Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ahn
Hyo Seop
HS
Cho
Bin
B
Choi
Yong-Mook
YM
Chung
Nack Gyun
NG
Hwang
Tai Ju
TJ
Im
Ho Joon
HJ
Jeong
Dae Chul
DC
Kang
Hyoung Jin
HJ
Koo
Hong Hoe
HH
Kook
Hoon
H
Kim
Hack Ki
HK
Lyu
Chuhl Joo
CJ
Seo
Jong Jin
JJ
Shin
Hee Young
HY
Yoo
Keon Hee
KH
Won
Sung Chul
SC
Lee
Kun Soo
KS
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy / Q000401:mortality; D004358:Drug Therapy / Q000401:mortality*; D005260:Female; D006801:Humans; D007223:Infant; D007723:Korea / Q000453:epidemiology; D008137:Longitudinal Studies; D008297:Male; D009447:Neuroblastoma / Q000401:mortality* / Q000628:therapy*; D015995:Prevalence; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D033581:Stem Cell Transplantation / Q000401:mortality*; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome